Hepatocellular carcinoma: Updates in primary prevention

被引：6

作者：

Fecht Jr. W.J. ^{[1
]}

Befeler A.S. ^{[1
]}

机构：

[1] Div. of Gastroenterology/Hepatology, Saint Louis Univ. School of Medicine, St. Louis, MO 63110-0250

来源：

Current Gastroenterology Reports | 2004年 / 6卷 / 1期

关键词：

Hepatocellular Carcinoma; Aflatoxin; Sustained Virologic Response; Glycyrrhizin; Hereditary Hemochromatosis;

D O I：

10.1007/s11894-004-0024-3

中图分类号：

学科分类号：

摘要：

Hepatocellular carcinoma is a significant cause of mortality worldwide and a growing problem in the United States. Treatment options are often limited, and median survival is less than 1 year, Thus, prevention may provide the best opportunity to alter the natural history of this disease. Primary prevention is best exemplified by the successes of such public health measures as universal hepatitis B vaccination. Such antiviral therapies as interferon may also have a role. Lessons can be learned from complementary and alternative medicine, Nevertheless, more work is needed in understanding hepatocarcinogenesis and in developing models to assess potential chemopreventive agents. Copyright © 2004 by Current Science Inc.

引用

页码：37 / 43

页数：6

共 49 条

[21] Baffis V., Shrier I., Sherker A., Et al., Use of interferon for prevention of hepatocellular carcinoma in cirrhotic patients with hepatitis B or hepatitis C virus infection, Ann. Intern. Med., 131, pp. 696-701, (1999)
[22] Colombo M., Hepatocellular carcinoma in patients with HCV, Baillieres Best Pract. Res. Clin. Gastroenterol., 14, pp. 327-329, (2000)
[23] (2003)
[24] Jaeckel E., Cornberg M., Wedemeyer H., Et al., Treatment of acute hepatitis C with interferon alfa-2b, N. Engl. J. Med., 345, pp. 1452-1457, (2001)
[25] Fried M.W., Shiffman M.L., Reddy K.R., Et al., Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection, N. Engl. J. Med., 347, pp. 975-982, (2002)
[26] Shiratoi Y., Imazeki F., Moriyama M., Et al., Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy, Ann. Intern. Med., 132, pp. 517-524, (2000)
[27] Di Bisceglie A.M., Carithers R.L., Gores G.J., Hepatocellular carcinoma, Hepatology, 28, pp. 1161-1165, (1998)
[28] Donato F., Boffetta P., Puoti M., A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma, Int. J. Cancer, 75, pp. 347-354, (1998)
[29] Tagger A., Donato F., Ribero M.L., Et al., Case-control study on hepatitis C virus (HCV) as a risk factor for hepatocellular carcinoma: The role of HCV genotypes and the synergism with hepatitis B virus and alcohol, Int. J. Cancer, 81, pp. 695-699, (1999)
[30] Mori M., Hara M., Wada I., Et al., Prospective study of hepatitis B and C viral infections, cigarette smoking, alcohol consumption, and other factors associated with hepatocellular carcinoma risk in Japan, Am. J. Epidemiol., 151, pp. 131-139, (2000)

← 1 2 3 4 5 →